Showing results (471-480 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|May 27, 1999
Consensus guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care settingM J WhitakerPharmacoeconomics|May 27, 1999
A review of quality of life in Alzheimer's disease. Part 2: Issues in assessing drug effectsS S Salek, M D Walker, A J BayerPharmacoeconomics|May 27, 1999
The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelinesJ M McKenneyPharmacoeconomics|February 1, 2006
Costs of irritable bowel syndrome in the UK and USStefanie Maxion-Bergemann, Frank Thielecke, Florian Abel, et al.Pharmacoeconomics|January 19, 2006
Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness modelsAlan HaycoxPharmacoeconomics|January 19, 2006
Modelling the treated course of schizophrenia: development of a discrete event simulation modelBart Heeg, Erik Buskens, Martin Knapp, et al.Pharmacoeconomics|January 19, 2006
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysisDiana De Graeve, Ann Smet, Angelika Mehnert, et al.Pharmacoeconomics|December 20, 2007
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysisGabriel Rogers, Ruth Garside, Stuart Mealing, et al.Pharmacoeconomics|January 18, 2008
Modelling methods for pharmacoeconomics and health technology assessment: an overview and guideJames E StahlPharmacoeconomics|January 18, 2008
The burden of schizophrenia on caregivers: a reviewA George Awad, Lakshmi N P VorugantiPageof 335